Key Takeaways
- Remicade (infliximab) is FDA-approved for several inflammatory and autoimmune conditions beyond rheumatoid arthritis (RA), including psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis.
- All of these conditions involve an overactive immune system that produces too much tumor necrosis factor (TNF), which is why the same biologic can treat several different diagnoses.
- Each condition has its own dosing schedule and treatment goals, so a patient's specific diagnosis determines how Remicade is used.
- Following a specialist's individualized treatment plan, rather than assuming every Remicade patient follows the same schedule, is central to getting the most benefit from therapy.
- Suite Life provides Remicade infusion therapy for RA and these related conditions at locations across Massachusetts and Rhode Island. Patients with a referral for any of these diagnoses can request an appointment to begin treatment.
Rheumatoid Arthritis Is Only Part of the Picture
Rheumatoid arthritis is one of the most common reasons patients are referred for Remicade infusion therapy, but it is far from the only one. Remicade was actually approved by the FDA for Crohn's disease first, in 1998, before its approval for RA followed in 1999. Since then, the FDA approval history for Remicade shows the medication has expanded to cover ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and plaque psoriasis as well.
In addition, your physician may recommend using it for other diseases that have not been formally approved by the FDA, such as uveitis, Behcet's disease, or sarcoidosis.
This blog focuses on the additional joint-related conditions Remicade treats: psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis.
Psoriatic Arthritis
Psoriatic arthritis is a form of inflammatory arthritis that develops in some people who have psoriasis, a skin condition marked by red, scaly patches. Psoriatic arthritis causes joint pain, stiffness, and swelling in addition to skin symptoms, and it can affect fingers, toes, and larger joints.
Remicade was approved for psoriatic arthritis in 2005 and works the same way it does for RA: by blocking TNF activity to reduce inflammation and, according to the FDA prescribing information, by inhibiting the progression of structural joint damage and improving physical function. According to a national CDC-funded analysis, an estimated 1.0 million U.S. adults with diagnosed arthritis have psoriatic arthritis specifically, making it far less common than RA but still a significant reason patients are referred for biologic therapy. Estimates vary depending on how psoriatic arthritis is defined. New England Journal of Medicine review reports a prevalence of 6 to 25 cases per 10,000 people in the United States, depending on the case definition.
Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis (JIA) is the term for arthritis that begins before age 16 and persists for at least six weeks without another identifiable cause. Like adult RA, JIA involves inflammation in the joints that can lead to pain, swelling, and, without treatment, long-term joint damage.
Remicade's use in JIA has been studied specifically in pediatric patients, and treatment decisions for children are made carefully by a pediatric rheumatologist based on the child's age, weight, and disease activity. Families exploring infusion therapy for a child with JIA should discuss the option directly with their child's rheumatology provider, since pediatric dosing and monitoring differ from adult protocols.
Ankylosing Spondylitis
Ankylosing spondylitis (AS) is a type of inflammatory arthritis that primarily affects the spine, causing pain and stiffness that can gradually reduce flexibility. Over time, untreated AS can lead to new bone formation along the spine, which may further limit movement.
Remicade was approved for AS in 2004, with a maintenance schedule (typically every six weeks) that differs slightly from its RA schedule (typically every eight weeks). Reducing the signs and symptoms of active AS is the primary treatment goal, helping patients maintain mobility and manage pain.
Why the Same Biologic Can Treat Multiple Conditions
RA, psoriatic arthritis, JIA, and AS are different diagnoses, but they share an underlying feature: each involves the immune system producing excess TNF, a protein that drives inflammation. Because Remicade works by blocking TNF rather than targeting a single disease process, it can be effective across this group of related inflammatory conditions, even though the joints affected and the specific symptoms can look quite different from one diagnosis to the next.
The table below compares a few key differences among these conditions.
RA, psoriatic arthritis, JIA, and AS are different diagnoses, but they share an underlying feature: each involves the immune system producing excess TNF, a protein that drives inflammation. Because Remicade works by blocking TNF rather than targeting a single disease process, it can be effective across this group of related inflammatory conditions, even though the joints affected and the specific symptoms can look quite different from one diagnosis to the next.
The table below compares a few key differences among these conditions.
| Condition | Primary Area Affected | Typical Remicade Maintenance Schedule |
|---|---|---|
| Rheumatoid arthritis | Small and large joints, often symmetrical | Every 8 weeks (with methotrexate) |
| Psoriatic arthritis | Joints and skin | Every 8 weeks |
| Juvenile idiopathic arthritis | Joints, in patients under 16 | Determined by pediatric rheumatologist |
| Ankylosing spondylitis | Spine and pelvis | Every 6 weeks |
The Importance of Following a Specialist's Treatment Plan
Because dosing, frequency, and treatment goals vary by condition and by how each patient responds, patients should follow the specific plan their rheumatologist or pediatric rheumatologist has prescribed rather than assuming their schedule matches another patient’s. A neighbor or family member on Remicade for RA, for example, may be on a different maintenance interval than someone being treated for AS.
Suite Life's clinical team administers each infusion according to the referring provider's prescription and works directly with that provider to track how a patient is responding over time.
One Biologic, Several Paths to Relief
Remicade's reach extends well beyond rheumatoid arthritis. For patients living with psoriatic arthritis, juvenile idiopathic arthritis, or ankylosing spondylitis, the same TNF-blocking biologic may offer a path toward less pain, less stiffness, and better long-term joint health, guided by a specialist who understands the specific condition being treated.
Patients referred for Remicade infusion therapy for any of these conditions can request an appointment at a Suite Life location across Massachusetts and Rhode Island to get started.
Frequently Asked Questions
Can Remicade treat conditions other than rheumatoid arthritis?
Yes. Remicade is FDA-approved for several inflammatory and autoimmune conditions beyond RA, including psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
Is the Remicade dosing schedule the same for every condition?
No. Maintenance schedules vary by condition. For example, RA and psoriatic arthritis are typically dosed every eight weeks, while ankylosing spondylitis is typically dosed every six weeks. A prescribing provider determines the exact schedule.
How do I know if I have psoriatic arthritis or rheumatoid arthritis?
Only a rheumatologist can make that diagnosis, typically through a combination of physical examination, imaging, and bloodwork. Psoriatic arthritis often, but not always, occurs alongside psoriasis skin symptoms, while RA does not involve skin plaques.
Where can I find infusion centers near me for these conditions?
Suite Life offers Remicade infusion therapy for RA, psoriatic arthritis, ankylosing spondylitis, and other conditions at locations across Massachusetts and Rhode Island. A referral from a rheumatologist or pediatric rheumatologist is required to begin treatment.
Can children receive Remicade infusion therapy?
Remicade has been studied in pediatric patients for certain conditions. Any decision to treat a child with Remicade should be made by a pediatric rheumatologist or gastroenterologist based on the child's specific diagnosis, age, and weight.
